EMBRAPII + SEBRAE Innovation for Small Businesses and Startups

EMBRAPII + SEBRAE Innovation Support for Small Businesses and Startups

Funds Brazilian micro and small businesses building technology projects through SEBRAE-backed EMBRAPII co-funding.

EMBRAPII and SEBRAE administer this non-reimbursable project co-funding route for Brazilian micro and small businesses and startups under their joint innovation support partnership. The page describes technical and financial support for development of new technology solutions, with projects contracted through EMBRAPII units rather than a standard public edital.

The funding mechanics combine EMBRAPII project support with SEBRAE coverage of part of the company's required counterpart. EMBRAPII can provide up to 50 percent of total project value, while SEBRAE can cover up to 70 percent of the counterpart set for micro and small businesses. The source states that the combined support can cover up to 90 percent of the innovation project without repayment at the end. The largest stated modality is BRL 300,000 for a project that joins multiple micro and small businesses and can include medium or large companies or investment funds as partners.

The direct applicant path is for Brazilian micro and small businesses with annual revenue up to BRL 4.8 million, and the page also names startups. A company should use this where it has a technology or product development project that can be scoped with an EMBRAPII unit. The company still needs to negotiate the remaining counterpart with the EMBRAPII unit, so the page should not be read as a cash grant paid directly into the company for unrestricted spending.

The official page does not publish a fixed deadline, scoring rubric, or public call document. It describes contracting as agile and without an edital, so this record treats the route as open while the EMBRAPII + SEBRAE page remains live. Practical risk is fit: the company needs a real innovation project, a matching EMBRAPII unit, and enough counterpart budget for whatever share remains after EMBRAPII and SEBRAE support.